Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

NCT00089245 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

177

Enrollment

INDUSTRY

Sponsor class

Stopped Corporate business decision. No safety or efficacy concerns.

Conditions

Brain and Central Nervous System Tumors
Neuroblastoma
Sarcoma

Interventions

DRUG: Iodine I 131 MOAB 8H9
DRUG: Iodine I 131 MOAB 8H9

Sponsor

Y-mAbs Therapeutics

Collaborators

[object Object]